Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

The Kings looked, for the first time in a long time, like a competent franchise, one with a future ahead of it. Even that season ending with a first-round loss to the Warriors couldn't put a damper on ...